SIC-19
SIC-19 is a SIK2 inhibitor and promotes SIK2 protein degradation via the ubiquitination pathway. SIC-19 inhibits cancer cell growth and sensitizes cells to PARP inhibitors (Such as Olaparib ), as well as in ovarian cancer organoids and xenograft models[1].
Product Specifications
CAS Number
713112-69-7
UNSPSC
12352005
Target
Salt-inducible Kinase (SIK)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sic-19.html
Purity
98.0
Solubility
DMSO : 2.5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(NC1=C(C(NNC(NC(C2=CC=CC=C2)=O)=S)=O)C(C3=CC=C(OC)C(OC)=C3)=C(C)S1)C4=CC=CC=C4
Molecular Formula
C29H26N4O5S2
Molecular Weight
574.67
References & Citations
[1]Wang F, et al. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer. Drug Resist Updat. 2024 May;74:101077.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
SIK2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GA100236 1 Kit
Human Apolipoprotein A I (APOA1) activation kit by CRISPRa
Sign In for Pricing
View Details 
TP305458M 100 µg
WBS28 (WBSCR28) (NM_182504) Human Recombinant Protein
Sign In for Pricing
View Details 
